FDA Panel Will Discuss COVID Rebound Cases During Paxlovid Meeting

Analyses conducted by FDA and Pfizer did not find a clear link between Pfizer’s COVID-19 drug Paxlovid, which is currently available under emergency use authorization, and coronavirus rebound cases, FDA says in briefing documents released ahead of the agency’s Thursday (March 16) meeting to discuss the drug. But the agency wants its advisers to weigh in on the issue and share whether they think there’s strong evidence showing a potential link between rebound and treatment with Paxlovid. The agency also...